Intrathoracic lipotoxicity is the consequence of increased accumulation and biological activity of various fat deposits in obesity, more specifically epicardial ("fat around the heart") and intramyocardial fat ("fat within the myocardium"). Epicardial fat is located in close proximity to the coronary arteries within the visceral pericardial layer (in contrast to the paracardial or mediastinal fat outside the pericardial layer). The epicardial fat originates embryologically from specific mesothelial cells with a vascular supply from the coronary arteries (1) . Epicardial adipose tissue appears to be biologically active by excreting paracrine and vasocrine factors that influence local and distant locations. Bioactive molecules like adiponectin are secreted by the epicardial fat and are transported to the myocardium and coronary endothelium through diffusion in the interstitial fluid and via the vasa vasorum. Adiponectin modulates the crosstalk between adipose tissue and the vasculature by inducing nitric oxide production (2) . Epicardial fat volume and adiponectin have been shown to be associated with coronary vasoreactivity of coronary microcirculation and coronary atherosclerosis (2) .
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A large number of alterations mediated by bioactive molecules and cellular mechanisms (e.g., infiltration of macrophages) may occur in epicardial fat, contributing to detrimental effects on cardiac function, coronary vasculature, and pulmonary function (1, 3, 4) . Macrophages play a central role in promoting the inflammatory response in adipose tissue in obesity-related disorders. Toxic intermediates of lipid metabolism (e.g., ceramide) may activate the inflammasomes-multiprotein complexes that sense damage-in macrophages, which infiltrate fat deposits, inducing the transition from obesity to insulin resistance and overt type 2 diabetes mellitus (5, 6) . Activated macrophages mediate the downregulation of adipocyte apolipoprotein E expression with site-specific differences for various fat compartments in obesity, and thereby, may promote the development of coronary artery disease (7) . Apolipoprotein E gene expression is highest in epicardial adipose tissue compared with other fat deposits like epicardial and visceral fat, and may have a protective effect against atherosclerosis (7) . Medication may have a differential effect on various fat compartments in patients with obesity-related disorders. For example, treatment of patients with type 2 diabetes mellitus using pioglitazone increases pericardial fat volume, whereas treatment with metformin does not affect the amount of pericardial fat (8) . Pioglitazone is implicated in the physiological regulation of adipocyte apolipoprotein E expression, possibly providing a link between drug action and site-specific effects (7) . Furthermore, epicardial fat may serve as brown fat to the myocardium by generating heat in response to cold temperatures and activation of the autonomic nervous system (9) .
Intramyocardial fat can also play a role in causing cardiac dysfunction in obesity-related disorders. This so-called myocardial lipotoxicity is now recognized as an important mechanism in heart failure and insulin resistance (10) . Pathological lipid accumulation in the myocardium is evidenced by increased levels of toxic lipid intermediates (e.g., diacylglycerol and ceramide), which are linked to mitochondrial dysfunction, insulin resistance, and apoptosis. Interestingly, mechanical unloading by using ventricular assist device implantation may reverse the negative effects of insulin resistance and toxic lipid intermediates in the failing heart (10). In addition, it has been shown that prolonged caloric restriction in obese patients with type 2 diabetes mellitus is associated with decreasing myocardial triglycerides content and improved diastolic function, indicating that presumed lipotoxicity is reversible and amendable by metabolic intervention (11) .
In particular, the usefulness of magnetic resonance imaging (MRI) and MR proton spectroscopy for assessing fat accumulation in and around the heart has revived the recognition of intrathoracic, and more specifically, myocardial lipotoxicity as an important contributing factor in causing heart failure in obesity-related disorders (12, 13) . MRI is well suited to estimate the amount of localized fat deposits like epicardial, paracardial, and visceral fat. Furthermore, proton MR spectroscopy is uniquely well suited to probe the amount of intramyocardial triglycerides accumulation noninvasively (14, 15) . Toxic lipid intermediates are implicated in insulin resistance, apoptosis, and lipotoxic cardiomyopathy. It is likely that lipotoxic cardiomyopathy is highly prevalent in the western population, knowing the epidemic proportions of obesity-related disorders, but at the From the Department of Radiology, Leiden University Medical Center, Leiden,same time, it is a potentially preventable heart disease. Lifestyle intervention, medication, and mechanical unloading the heart may reverse or prevent lipotoxic cardiomyopathy. For example, it was shown that pioglitazone significantly reduces myocardial and hepatic steatosis in patients with type 2 diabetes mellitus who were treated with insulin (16) . The study by Gaborit et al. (17) in this issue of the Journal reports on the effects of bariatric surgery on pericardial fat, visceral fat, and myocardial triglyceride content assessed by advanced MRI technology. As expected, bariatric surgery significantly reduced body mass index (BMI), improved glycemic control, and decreased subcutaneous fat, visceral fat, and epicardial fat at 6-month follow-up. However, there was no significant decrease in myocardial triglycerides after bariatric surgery, although the myocardial triglycerides were increased at baseline. Weight loss was associated with a decrease in cardiac output and left ventricular mass and an improvement in diastolic heart function in particular. Of note, epicardial fat loss was not associated with changes in BMI or visceral fat loss, indicating possible disparate effects of bariatric surgery on various fat deposits. Patients with sleep apnea syndrome had a lesser decrease in epicardial fat compared with those without the syndrome. Furthermore, the type of surgery did not appear to result in differences in weight loss or epicardial fat loss, although only 25 patients were included (19 sleeve gastrectomies, 5 Roux-en-Y gastric bypass operations, and 1 adjustable gastric banding). This study highlights the disparate biological responses of various ectopic fat deposits and cardiovascular function after bariatric surgery (17) . The differential changes in epicardial fat loss after bariatric surgery and the suggested relationship with the sleep apnea syndrome seem to indicate a depositspecific biological effect. In line with a possible disparate effect on various fat deposits, previous studies showed a long-term beneficial and sustained effect on pericardial fat loss with diet intervention in obese, type 2 diabetes mellitus patients, despite weight regain at long-term follow-up (18) .
The lack of a decrease in myocardial triglycerides after bariatric surgery reported in this study is somewhat puzzling, because cardiovascular function improved, indicating a biological effect to the myocardium. Underpowering of the study may possibly account for the lack of demonstrating a decrease of myocardial triglycerides in conjunction with an improvement in diastolic left ventricular function. In contrast, it has been suggested that a decrease in myocardial triglycerides may not be a prerequisite for improved ventricular function after metabolic intervention (3). Overall, the study of Gaborit et al. (17) illustrates the strength and utility of noninvasive MRI tools for probing multiple fat deposits and cardiovascular function in a single examination for evaluating the effects of metabolic and/or bariatric surgery in obesity.
In general, MRI and spectroscopy have great potential to evaluate multiple relevant imaging biomarkers to assess the cardiovascular risk in obesity and obesity-related disorders (19) . Proton spectroscopy is the most accurate noninvasive method to estimate liver fat, which is strongly related to insulin resistance, atherogenic dyslipidemia, and higher circulating inflammatory biomarkers (19) . Furthermore, obesity and the metabolic syndrome are associated with accelerated arterial aging and increased arterial stiffness, which can be estimated as pulse-wave velocity and aortic distensibility with the aid of MRI (19) . For example, local aortic stiffness measured by MRI is independently associated with systolic left ventricular function, cerebral white matter disease, and renal function in diabetic patients, illustrating the systemic nature of diabetes involving multiple organs (20 -22) . Interestingly, obesity-related disorders are related to cerebral atrophy, white matter lesions, and brain infarctions that may contribute to early cognitive decline and dementia (23) . In addition to the measurement of increased accumulation of epicardial and intramyocardial fat, MRI offers great versatility to define multiple other cardiovascular risk factors, such as small, silent myocardial infarction, the ischemic cascade culminating in overt myocardial infarction, and diffuse myocardial fibrosis in patients with obesity-related disorders (19, 24) . Moreover, phosphorus 31 MR spectroscopy of the liver may be helpful to probe intermediates of membrane metabolism that signal the transition from uncomplicated liver steatosis to steatohepatitis (nonalcoholic steatohepatitis) (19) .
In conclusion, bariatric surgery has a substantial effect on weight loss, but the mechanism of action is poorly understood (25) . In particular, the nonweight loss effect of bariatric surgery has raised interest in the surgical option as a treatment for subjects with type 2 diabetes mellitus. It is evident that the versatility of MRI techniques for multiorgan imaging may be well suited to define selection criteria, establish mechanisms of surgical intervention, and assess long-term multiorgan effects after metabolic and/or bariatric intervention.
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